Re: Algún comentario sobre bayer ??
Te acompaño , acabo de entrar 76'5. Los cuchillos cayendo son para valientes . saludos y suerte
Te acompaño , acabo de entrar 76'5. Los cuchillos cayendo son para valientes . saludos y suerte
esperare a resultados a primeros de septiembre, no creo que la bajada bestial que tuvo sea solo del tema del cancer.
Vendidas + 7 ℅ en una semana . Volveré a comprar si baja ..me tiraré de los pelos si sube pero más vale pájaro en mano k..... Saludos
LEO Pharma and Bayer announced today the completion of the relevant closing conditions to allow the transfer of Bayer’s prescription dermatology business to LEO Pharma in the United States. Closing in all other countries is expected during the second half of 2019, subject to the fulfillment of customary closing conditions.
LEO Pharma and Bayer entered into an agreement for the acquisition of Bayer’s global portfolio of prescription dermatology products as announced on July 31, 2018. This includes Finacea® (azelaic acid) Foam for the topical treatment of mild to moderate rosacea, a range of topical steroids and other products for the treatment of acne and fungal skin infections.
Chris Posner, President and CEO of LEO Pharma US, said: “This is an exciting time for LEO Pharma in the US. Completing this acquisition enables LEO Pharma US to significantly broaden its therapeutic areas and skilled workforce, ultimately providing more treatment options for dermatology patients across the country.” “Our Rx Dermatology colleagues have worked diligently to develop this business over many years,” said Patrick Lockwood-Taylor, President of Bayer’s Consumer Health business in North America. “With the closing of the transaction in the US, the business is now in the best hands for future growth and allows Bayer to focus on our core OTC business. I want to thank the Bayer and LEO teams for their great collaboration that brought us to this milestone in such a short period of time.” As announced as part of the agreement, LEO Pharma will acquire the global product rights, except for Afghanistan and Pakistan, and take over the sales and marketing LEO Pharma closes acquisition of Bayer’s prescription dermatology business in the United States - 2/3 - organizations in 14 countries, as well as a factory in Segrate, Italy.
Assuming the successful close, around 450 people will join LEO Pharma as part of this transaction. Subject to applicable laws, LEO Pharma and Bayer will continue to work closely together with the aim of securing an effective transition of the business in the rest of the world and an uninterrupted supply of prescription dermatology treatments that patients have come to rely on and trust.
Bayer Group presenta los resultados del 2T2018. En ellas podemos destacar que los beneficios netos se han reducido un 35% con respecto al 2T2017, pasando a ser de 799 millones de Euros. Los resultados completos se pueden consultar en el siguiente enlace a la CNMV.
Principales Datos Financieros
Datos más significativos del Negocio
Estimaciones de Renta 4 para 2018
Vuelvo a 76,3. A ver si tengo suerte de nuevo. Saludos
Saludos.... sabes si hay doble imposición en los dividendos de Bayer, en la bolsa Española....
Es que la estoy siguiendo, por la bajada de precio parece interesante
Hola,
Si que hay doble retención, aunque cotice en la bolsa española, la retención se produce según el pais de origen